Technical Analysis for GPCR - Structure Therapeutics Inc.

Grade Last Price % Change Price Change
C 22.43 -0.13% -0.03
GPCR closed down 0.13 percent on Wednesday, March 22, 2023, on 62 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Outside Day Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -0.13%
Gapped Up Strength -0.13%
Down 3 Days in a Row Weakness -0.13%
20 DMA Resistance Bearish -1.02%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 20 DMA about 15 hours ago
Rose Above Previous Day's High about 15 hours ago
Rose Above 10 DMA about 15 hours ago
Up 5% about 15 hours ago
Up 3% about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Structure Therapeutics Inc. Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Molecular Biology Obesity Signal Transduction Chronic Disease Pulmonary Arterial Hypertension Diabetes Mellitus Idiopathic Pulmonary Fibrosis Biochemistry Glucagon Receptor

Is GPCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 28.5
52 Week Low 20.8001
Average Volume 70,872
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 23.89
10-Day Moving Average 23.08
Average True Range 2.39
RSI 39.39
ADX 26.04
+DI 19.82
-DI 12.68
Chandelier Exit (Long, 3 ATRs) 21.34
Chandelier Exit (Short, 3 ATRs) 27.96
Upper Bollinger Bands 26.33
Lower Bollinger Band 21.44
Percent B (%b) 0.2
BandWidth 20.46
MACD Line -0.21
MACD Signal Line 0.04
MACD Histogram -0.2444
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.64
Resistance 3 (R3) 25.97 25.23 25.11
Resistance 2 (R2) 25.23 24.41 25.07 24.93
Resistance 1 (R1) 23.83 23.91 23.46 23.50 24.75
Pivot Point 23.09 23.09 22.91 22.93 23.09
Support 1 (S1) 21.69 22.27 21.32 21.36 20.11
Support 2 (S2) 20.95 21.77 20.79 19.93
Support 3 (S3) 19.55 20.95 19.76
Support 4 (S4) 19.22